Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AQW051 (VQW-765) is an orally active alpha-7 nicotinic acetylcholine receptor (α7-nAChR) specific activator that interacts with recombinant human α7-nAChR expression (pKD value 7.56). Alpha7-nachr is considered an attractive target for the treatment of cognitive impairments associated with neurological disorders, so VQW-051 is often used in studies of anxiety disorders and acute anxiety.
説明 | AQW051 (VQW-765) is an orally active alpha-7 nicotinic acetylcholine receptor (α7-nAChR) specific activator that interacts with recombinant human α7-nAChR expression (pKD value 7.56). Alpha7-nachr is considered an attractive target for the treatment of cognitive impairments associated with neurological disorders, so VQW-051 is often used in studies of anxiety disorders and acute anxiety. |
ターゲット&IC50 | α7 nAChR:7.41(pEC50) |
In vitro | AQW-051 binds to recombinant human α7-nACh receptor with a pKD value of 7.56. AQW051 effectively activated the calcium transient in GH3-ha7-22 cells stimulated by recombinant expression of α7-nACh receptor, with a pEC50 value of 7.41[1]. |
In vivo | Mice administered orally with AQW051 at 0.03 and 0.3 mg/kg enhances cognitive effects and learning/memory performance. Orally AQW051 1mg/kg each time in rats increasing the social exploration time, demonstrating the antianxiety effect of AQW051[1]. |
別名 | AQ W051, VQW-765, AQW-051 |
分子量 | 294.39 |
分子式 | C19H22N2O |
CAS No. | 669770-29-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 4.4 mg/mL (14.95 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AQW051 669770-29-0 Neuroscience AChR AQ W051 AQ W 051 VQW765 AQW 051 VQW 765 VQW-765 AQW-051 AQ W-051 Inhibitor inhibitor inhibit